Business
ZYUS Life Sciences Announces Cancellation of LIFE Offering and Launch of Private Placement
ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, today announces the Company has elected to cancel its previously announced brokered private placement offering (the "LIFE Offering"), which was originally announced on January 12, 2026 and amended and restated on February 9, 2026. As a result, no securities will be issued, and the Company will
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"SASKATOON, SK, Feb. 24, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, today announces the Company has elected to cancel its previously announced brokered private placement offering (the "LIFE Offering"), which was originally announced on January 12, 2026 and amended and restated on February 9, 2026. As a result, no securities will be issued, and the Company will not receive any proceeds from the offering.","length":601,"tagName":"p"},{"type":"image","alt":"ZYUS Life Sciences Logo (CNW Group/ZYUS Life Sciences Corporation)","displaySize":"","headline":null,"caption":"ZYUS Life Sciences Logo (CNW Group/ZYUS Life Sciences Corporation)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":162,"url":"https://media.zenfs.com/en/cnwgroup.com/1c77aaa4432b1c05195fe7bc92438a2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PLuZby7jcwq5.mFipue2Pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4NjtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/1c77aaa4432b1c05195fe7bc92438a2e","width":400,"height":162}},"href":"https://mma.prnewswire.com/media/2919857/ZYUS_Life_Sciences_Corporation_ZYUS_Life_Sciences_Announces_Canc.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company further announces that it intends, subject to approval of the TSX Venture Exchange, to solicit subscriptions for a non-brokered private placement (the "Private Placement") of up to 11,111,111 units (each a "Unit") at a price of C$0.63 per Unit for aggregate gross proceeds of up to C$7,000,000. Each Unit will consist of one common share of the Company and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a "Warrant") at an exercise price of C$0.85 for a period of 24 months from the date of issuance. In connection with the Private Placement, the Company may pay certain eligible finders a cash fee in respect of the gross proceeds raised under the Private Placement.","length":735,"tagName":"p"},{"type":"text","content":"Additi...